Patents by Inventor Robert H. Purcell

Robert H. Purcell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Attenuated hepatitis a virus vaccine which grows in MRC-5 cells
    Patent number: 6180110
    Abstract: A live hepatitis A virus (HAV) adapted to grow in MRC-5 cells is described, the HAV preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation. Methods for adapting HAV to grow in MRC-5 cells, vaccine compositions comprising the attenuated HAV, and methods of vaccinating humans against HAV infection are also described.
    Type: Grant
    Filed: April 17, 1995
    Date of Patent: January 30, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ann W. Funkhouser, Suzanne U. Emerson, Robert H. Purcell, Eric D'Hondt
  • Methods for detecting antibodies to HAV 3C proteinase
    Patent number: 6156499
    Abstract: The present invention discloses methods for detecting antibodies to HAV 3C proteinase. These methods can distinguish an individual with a natural infection from one who has been vaccinated with an inactivated vaccine and are thus of utility in the diagnosis of hepatitis A in situations in which vaccination is widespread.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: December 5, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Deneen Stewart, Tina S. Morris, Robert H. Purcell, Suzanne U. Emerson
  • Cloned genomes of infectious hepatitis C viruses and uses thereof
    Patent number: 6153421
    Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.
    Type: Grant
    Filed: January 27, 1998
    Date of Patent: November 28, 2000
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Masayuki Yanagi, Jens Bukh, Suzanne U. Emerson, Robert H. Purcell
  • Human/simian chimeric hepatitis A virus vaccine
    Patent number: 6146643
    Abstract: The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 14, 2000
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Sergei A. Tsarev, Suzanne U. Emerson, Robert H. Purcell
  • Method for producing an adapted virus population from an African green monkey kidney cell line
    Patent number: 6117667
    Abstract: The invention described herein provides a method for selecting a novel African Green monkey kidney (AGMK) cell substrate, its cultivation and serial passage and its subsequent characterization. The invention provides a method for the use of the cell substrate in the isolation, growth and serial passage of a large number of viruses, particularly rotaviruses, enteroviruses, respiratory viruses and hepatitis A virus. The invention provides a method for the utilization of this AGMK cell substrate for the production of live and killed virus vaccines.
    Type: Grant
    Filed: June 21, 1999
    Date of Patent: September 12, 2000
    Assignees: Dyncorp, National Institutes of Health
    Inventors: Louis Potash, Robert M. Chanock, Robert H. Purcell, Albert Z. Kapikian
  • Hepatitis A virus vaccines
    Patent number: 6113912
    Abstract: A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 5, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ann W. Funkhouser, Suzanne U. Emerson, Robert H. Purcell, Eric D'Hondt
  • Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
    Patent number: 6110465
    Abstract: The nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of 49 isolates of hepatitis C are disclosed. The invention relates to the use of these sequences to design proteins and nucleic acid sequences useful in diagnostic methods and vaccines.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 29, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jens Bukh, Roger H. Miller, Robert H. Purcell
  • Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
    Patent number: 6054567
    Abstract: The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: April 25, 2000
    Assignees: The United States of America as represented by the Department of Health and Human Services, Novavax, Inc.
    Inventors: Suzanne U. Emerson, Robert H. Purcell, Sergei A. Tsarev, Robin A. Robinson
  • Method for producing a virus from an african green monkey kidney cell line
    Patent number: 6025182
    Abstract: A method for producing novel African Green Monkey Kidney (AGMK) cell lines is taught. These cell lines which are free of viable adventitious microbial agents are useful as substrates for viruses and for the preparation of viral vaccines.
    Type: Grant
    Filed: March 26, 1998
    Date of Patent: February 15, 2000
    Assignees: Dyncorp, National Institutes of Health
    Inventors: Louis Potash, Robert M. Chanock, Robert H. Purcell, Albert Z. Kapikian
  • Method of producing a virus vaccine from an African green monkey kidney cell line
    Patent number: 5911998
    Abstract: A method for producing novel African Green Monkey Kidney (AGMK) cell lines is taught. These cell lines which are free of viable adventitious microbial agents are useful as substrates for viruses and for the preparation of viral vaccines.
    Type: Grant
    Filed: January 29, 1997
    Date of Patent: June 15, 1999
    Assignees: Dyncorp, National Institutes of Health
    Inventors: Louis Potash, Robert M. Chanock, Robert H. Purcell, Albert Z. Kapikian
  • Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
    Patent number: 5882852
    Abstract: The nucleotide and deduced amino acid sequences of cDNAs encoding the envelope 1 genes and core genes of isolates of hepatitis C virus (HCV) are disclosed. The invention relates to the oligonucleotides, peptides and recombinant envelope 1 and core proteins derived from these sequences and their use in diagnostic methods and vaccines.
    Type: Grant
    Filed: August 15, 1994
    Date of Patent: March 16, 1999
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Jens Bukh, Roger H. Miller, Robert H. Purcell
  • Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods
    Patent number: 5871962
    Abstract: The nucleotide and deduced amino acid sequences of 51 cDNAs are disclosed where each cDNA encodes the envelope 1 gene of an isolate of hepatitis C virus (HCV). The invention relates to the oligonucleotides, peptides and recombinant envelope 1 proteins derived from these sequences and their use in diagnostic methods and vaccines.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 16, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jens Bukh, Roger H. Miller, Robert H. Purcell
  • Production of complementary DNA representing hepatitis A viral sequences by recombinant DNA methods and uses therefor
    Patent number: 5849562
    Abstract: Methods for producing HAV cDNA, products thereof, and uses thereof, are described. HAV cDNA is produced, for example, by reverse transcribing HAV RNA and subsequently inserting the HAV cDNA into bacterial plasmids by genetic-engineering techniques. Transformed bacteria are then cloned and cultured to produce replicated chimeric plasmids containing the HAV cDNA. Such HAV cDNA is useful in assaying for the presence of HAV and in the production of HAV antigen and in the production of antibodies against HAV.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 15, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert H. Purcell, Suzanne U. Emerson
  • Chimeric hepatitis A vaccine
    Patent number: 5837260
    Abstract: A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transfection of monkey kidney cells with pHAV/7 DNA yielded HAV. Transfection with RNA transcripts produced in vitro from pHAV/7 yielded about 10-fold more HAV than transfection with pHAV/7 DNA. HAV thus produced are useful as a vaccine.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: The United of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey I. Cohen, Robert H. Purcell, Stephen M. Feinstone, John R. Ticehurst
  • African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
    Patent number: 5646033
    Abstract: A novel African Green Monkey Kidney (AGMK) cell line is taught as well as a method for the preparation thereof. The cell line which is free of viable adventitious microbial agents is useful as a substrate for viruses and for the preparation of viral vaccines.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: July 8, 1997
    Assignees: Dyncorp, National Institutes of Health
    Inventors: Louis Potash, Robert M. Chanock, Robert H. Purcell, Albert Z. Kapikian
  • Methods of detecting hepatitis A virus
    Patent number: 5516630
    Abstract: Methods for producing HAV cDNA, products thereof, and uses thereof, are described. HAV cDNA is produced, for example, by reverse transcribing HAV RNA and subsequently inserting the HAV cDNA into bacterial plasmids by genetic-engineering techniques. Transformed bacteria are then cloned and cultured to produce replicated chimetic plasmids containing the HAV cDNA. Such HAV cDNA is useful in assaying for the presence of HAV and in the production of HAV antigen and in the production of antibodies against HAV.
    Type: Grant
    Filed: November 6, 1991
    Date of Patent: May 14, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: John R. Ticehurst, David Baltimore, Stephen M. Feinstone, Robert H. Purcell, Vincent R. Racaniello, Bahige M. Baroudy
  • Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
    Patent number: 5514539
    Abstract: The nucleotide and deduced amino acid sequences of 51 cDNAs are disclosed where each cDNA encodes the envelope 1 gene of an isolate of hepatitis C virus (HCV). The invention relates to the oligonucleotides, peptides and recombinant envelope 1 proteins derived from these sequences and their use in diagnostic methods and vaccines.
    Type: Grant
    Filed: June 29, 1993
    Date of Patent: May 7, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jens Bukh, Roger H. Miller, Robert H. Purcell
  • cDNA encoding attenuated cell culture adapted hepatitis A virus genome
    Patent number: 5478746
    Abstract: A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transfection of monkey kidney cells with pHAV/7 DNA yielded HAV. Transfection with RNA transcripts produced in vitro from pHAV/7 yielded about 10-fold more HAV than transfection with pHAV/7 DNA. HAV thus produced are useful as a vaccine.
    Type: Grant
    Filed: September 13, 1993
    Date of Patent: December 26, 1995
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey I. Cohen, Robert H. Purcell, Stphen M. Feinstone, John R. Ticehurst
  • Vaccine against hepatitis a comprising simian HAV isolate AGM-27
    Patent number: 5476658
    Abstract: The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.
    Type: Grant
    Filed: March 26, 1991
    Date of Patent: December 19, 1995
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Sergie A. Tsarev, Suzanne U. Emerson, Michael S. Balayan, Robert H. Purcell
  • Vaccine against hepatitis A virus
    Patent number: 4894228
    Abstract: The present invention provides an attenuated hepatitis A virus useful as a vaccine.
    Type: Grant
    Filed: July 12, 1988
    Date of Patent: January 16, 1990
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert H. Purcell, John R. Ticehurst, Jeffrey I. Cohen, Suzanne U. Emerson, Stephan M. Feinstone, Richard J. Daemer, Ian D. Gust